A CNS-focused biopharma needed to maintain sales of flagship products nearing loss of exclusivity while preparing for a major launch. The company redeployed its internal sales team to the launch and partnered with IQVIA to manage legacy brands. IQVIA quickly built a field force of eight regional directors and 85 reps, initially engaging top HCPs directly when the launch was delayed. Within one quarter, they drove 700 new prescriptions and later expanded to two flagship products. By end of 2021, IQVIA delivered 105% of forecast, accounting for 85% of annual revenue, proving both speed and cultural alignment.

Join for free to read